i
OR SCROLL THE EXPERIENCE
The power of precision medicine
is only growing stronger
55+ New
FDA-Approved Agents
Today

FDA-APPROVED: 90+ indications
COVERING: 25+ Cancers

From 2013 to 20201
In Development

Over 4200
active oncology trials in the US2

Over 1/3
of active oncology clinical
trials in the US use genomics
for patient selection3


91%
of oncology drugs in late-stage
pharma pipelines are targeted
therapies
5
A comprehensive approach to testing keeps you up to date with the most recent treatment options for your patients
*Recent approvals and label expansions
Select Targeted Therapies
Including Recent Approvals1
Why Comprehensive Genomic Profiling?
More insights and fewer missed opportunities from a single test.
Comprehensive Genomic Profiling
Detects the 4 main classes of genomic alterations across a broader panel of genes.

FOUNDATIONONE®CDx

Single Marker
Single biomarker testing identifies alterations confined to a single gene, resulting in potentially missing clinically relevant mutations in additional genes.

NeoGenomics ALK FISH Test

HotSpot
Gene hotspot testing may test multiple genes at a time, but is confined to hotspot regions within those genes, resulting in potentially missing other clinically relevant classes of alterations.

Oncomine Dx Target Test (Thermo Fisher)

Substitutions
InDels
Rearrangements
CNAs
Not Detected
More Information
Biomarkers shown in table above are examples of relevant and emerging biomarkers in non-small cell lung cancer (NSCLC).

NeoGenomics ALK FISH Test and Oncomine Dx are examples of single biomarker and hotspot tests.
EGFR
See Sample Report (link)
EGFR exon 19 deletion
KRAS
BRAF
ALK
ERBB2
KRAS
ROS1
NTRK1
NTRK2
NTRK3
RET
STK11
EGFR
KRAS
BRAF
ALK
ERBB2
KRAS
MET
ROS1
NTRK1
NTRK2
NTRK3
RET
STK11
EGFR
KRAS
BRAF
ALK
ERBB2
KRAS
MET
ROS1
NTRK1
NTRK2
NTRK3
RET
STK11

Did you know?

Updated guidelines now recommend comprehensive genomic profiling for even more cancer types.

Molecular testing is recommended by NCCN guidelines for a growing number of cancer types, including NSCLC, Breast, Prostate, Colon, Rectal, Ovarian, and Melanoma.

Genomic Signatures

LOH/HRD

Loss of Heterozygosity

Resulting from Homologous Recombination Deficiency (HRD), LOH has been shown to sensitize tumors to PARP inhibitors, particularly relevant to Ovarian cancer.

LOH can be determined through comprehensive genomic profiling.

MSI

Microsatellite Instability

A computational biomarker associated from defects in DNA mismatch repair as assessed through comprehensive genomic profiling.

Pembrolizumab is indicated for patients with MSI-H status across all solid tumor types when previous therapies have failed13.

TMB

Tumor Mutational Burden

A computational biomarker that quantifies the number of mutations found within a tumor as assessed through a large gene panel.

High TMB has been associated with improved response to immunotherapy1 4.

Integrating comprehensive genomic profiling into clinical practice

Complete Picture

More complete information on common oncogenic drivers and new information on complex or rare biomarkers all from a single test2,3.
+ 4 main types of genomic alterations
+ Broad gene panel >50

Efficiency

In some cases, sequential testing of single biomarkers or use of limited molecular diagnostic panels may quickly exhaust sample. In these scenarios, tissue or liquid comprehensive genomic profiling is recommended by professional guidelines4,5,6.
+ Eliminate need for sequential testing1,2,3

More Options

A study in NSCLC found that 44% of patients didn’t get results from molecular testing because tissue was insufficient1. In such cases, you need a portfolio that includes liquid-based comprehensive genomic profiling.
+ More information from each sample1,2,3

Continuously Evolving

Comprehensive genomic profiling can help you keep up to date with the most recent treatment options available throughout the patient’s treatment journey.
+ New approvals
+ Clinical trial data
Earlier use
A recent study of 266 advanced NSCLC patients found that 1 life year was saved for every 5 advanced patients tested with comprehensive genomic profiling compared to non-comprehensive genomic profiling molecular diagnostic testing when used to inform first-line treatment.6

Can improve OS1

A study evaluating 188 advanced cancer patients with genomic profiling data found promising outcomes for matched therapies when administered to a patient population undergoing comprehensive genomic profiling in earlier lines of therapy including improved observed overall survival.1

(≤3) vs (≥4)

Higher proportion of patients on matched therapy1

A study evaluating 188 advanced cancer patients with genomic profiling data found that the patient population who underwent comprehensive genomic profiling in earlier lines of therapy (lines 1 to 3; n=58) had a higher proportion of patients on matched therapy.1

(70.7% vs 62.3%)

Prevent contraindicated therapies

Use cases at each line of therapy for advanced cancer patients2,3,4,5

First Line2:
+ Develop treatment plan
+ Identify prognostic genes
Progression/Relapse2,3:
+ Uncover resistance mutations or new alterations
+ May help predict response to immunotherapies
Refractory2:
+ Investigate clinical trial options
+ Explore pan-tumor targeted therapies
Foundation Medicine began with an idea
— to simplify the complex nature of cancer genomics, bringing cutting-edge science and technology to everyday cancer care. In just a few years, that idea has evolved into best-in-class products and services that empower the work and research of physicians, researchers, and all those engaged in the fight against cancer around the globe.
More options,
all in one proven portfolio
ALL SOLID TUMORS:
Tissue Biopsy
  • FDA-approved CDx
  • National Coverage Determination for qualifying Medicare patients1
LATEST EVIDENCE FOUNDATIONONE®CDx INFO
ALL SOLID TUMORS:
Liquid Biopsy
  • Labratory Developed Test
LATEST EVIDENCE FoundationONe®LIQUID INFO
HEMATOLOGIC MALIGNANCIES
AND SARCOMAS
  • Labratory Developed Test
LATEST EVIDENCE FoundationONe®Heme INFO
All Solid Tumors: Tissue Biopsy
LATEST UPDATES
FoundationOne®CDx has been FDA-approved as the companion diagnostic test for TABRECTA™ (capmatinib)
Approximately 3% of NSCLC patients harbor a MET exon 14 mutation1. The recent FDA-approval of TABRECTA™ (capmatinib) expands clinical utility of broad genomic testing in NSCLC as the first targeted therapy for mutations that lead to MET exon 14 skipping.
Foundation Medicine has extensive experience in reporting mutations that lead to MET exon 14 skipping, and can help identify NSCLC patients who may be eligible for TABRECTA™ (capmatinib).1
TABRECTA PRESS RELEASE
All Solid Tumors: Tissue Biopsy
LATEST UPDATES
FoundationOne®CDx was approved as the companion diagnostic for Lynparza™ (olaparib) to identify patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
LynparzaTM (olaparib) was approved based on positive results from the PROfound study for which Foundation Medicine served as the NGS partner.
Results from the PROfound study showed a 33% objective response rate for HRR-positive patients treated with olaparib2.
FoundationOne®CDx covers all HRR pathway genes recommended by professional guidelines, which include BRCA1/2 and ATM 3.
LYNPARZA PRESS RELEASE
All Solid Tumors: Liquid Biopsy
LATEST UPDATES
FoundationOne®Liquid identified breast cancer patient likely to respond to alpelisib1.
Multiple PIK3CA mutations is a frequent occurrence in metastatic breast cancer patients. Use of comprehensive genomic profiling determined this may occur in as many as 20% of breast cancer patients.
These mutations are typically missed by hotspot testing.
SEE PUBLICATION SUMMARY
All Solid Tumors: Liquid Biopsy
LATEST UPDATES
FoundationOne®Liquid identified patients with ALK fusions in NSCLC who could be treated with alectinib2.
Only liquid biopsy test able to identify patients with ALK fusions in a global prospective trial for metastatic NSCLC at similar frequencies to tissue testing
5.4% for FoundationOne®Liquid2 vs. 5% historically with tissue testing3
SEE PUBLICATION SUMMARY
Hematologic Malignancies and Sarcomas
LATEST EVIDENCE
FoundationOne®Heme remains CGP test of choice for the Beat AML TRIAL.
Though several targeted therapies have recently been approved in AML, with more in development, the standard approach to treatment has changed little in the past 40 years. More treatment options are needed, especially for people over age 60.
An abstract presented at ASH 2019 confirmed the feasibility of delivering CGP results within seven days of diagnosis, the safety of waiting up to seven days to initiate treatment, and the value of applying a precision medicine approach to inform treatment assignment1.
SEE SUMMARY ON OUR BLOG
Hematologic Malignancies and Sarcomas
LATEST EVIDENCE
FoundationOne®Heme identifies a rare new sarcoma subtype.
Previously considered a subtype of Ewing’s sarcoma and treated as such, the EWSR1-NFATc2 fusion was shown to result in a unique sarcoma subtype - molecularly distinct from Ewing’s sarcoma.
Researchers reported one patient with EWSR1-NFATc2 fusion was treated with an mTOR inhibitor and had “extraordinary long-term disease stabilization,” setting the stage for investigation of a targeted treatment for these patients.
The ability to identify such a small subset (0.076%), made possible by our more than 350,000 genomic profiles within the FoundationCore® database2.
SEE SUMMARY ON OUR BLOG
Your Trusted Partner

MOST EXPERIENCE WITH COMPREHENSIVE
GENOMIC PROFILING

  • Over 450 peer-reviewed publications
  • 400,000 patients tested in a clinical setting1
  • First FDA-approved broad companion diagnostic for all solid tumors

LEARN MORE
More Support
Provider Services
Workflow Integration
  • Integrate into your current testing workflow
  • Liquid-based test to offer flexibility in sample submission and reflex option from tissue
  • EMR interfacing options
  • Digital Experience: online ordering,
    simplified digital reporting and mobile app

LEARN MORE

Decision Support

MEDICAL CASE CONSULTING
Provided by a team of oncologists and
pathologists to discuss patient results

MOLECULAR TUMOR BOARDS
for eligible institutions to educate on the
actionability of CGP through clinical case
report interpretations

LEARN MORE
With 20+ FDA-approved CDx indications,
FoundationOne®CDx offers the most direct
paths to targeted therapie
s to inform
treatment strategies for your patients.


LEARN MORE
Clinical Utility

Beyond guideline-recommended and
emerging biomarkers, comprehensive
genomic profiling has demonstrated
clinical utility outside of companion
diagnostic claims.
Financial Assistance
and Coverage

  • Medicare and TRICARE cover
    FoundationOne®CDx for qualifying patients2
  • Commercial payers, such as Cigna and many
    Blue Cross Blue Shield plans
    , offer coverage
    for Foundation Medicine testing services3
  • Financial assistance is available for patients
    based on need and can be applied for at any
    point during the testing process

LEARN MORE
Biopharma Services
EXTRACT KEY DATA INSIGHTS from our database, FoundationCore, with over 400k patients profiled

LEARN MORE
ACCESS CLINICO-GENOMIC MOLECULAR OUTCOMES DATA THROUGH the clinico-genomic database (CGDB) we have developed in partnership with Flatiron Health

LEARN MORE

Clinical Trial Solutions

END-TO-END SUPPORT WITH FOUNDATIONSMARTTRIALS helps to identify new targets, optimize trial design, and screen patients for enrollments who meet specific genomic criteria

CONNECT WITH ELIGIBLE PARTNERS that match your target profile and physicians interested in working with you on your trial with Precision Enrollment

See FoundationSmartTrials FOUNDATION MEDICINE AND OPTIMAL PARTNERSHIP enables speedy clinical trial enrollment

VIEW CASE STUDY
Companion Diagnostic

(CDx) Development


MITIGATE RISKS in CDx development by utilizing our comprehensive genomic profiling platform within our QSR-compliant laboratory

SUPPORT THROUGHOUT THE PROCESS with end-to-end integrated solution support

IMPROVE TIMELINE EFFICIENCY by leveraging our existing FDA-approval as a broad CDx which can potentially reduce companion diagnostic development timelines for your team

LEARN MORE
Trusted partner across the globe
Together, Roche and Foundation Medicine are bringing comprehensive genomic profiling to cancer patients around the world, combining Roche’s expertise and commitment in oncology and Foundation Medicine’s leading technology, validation and experience in cancer profiling1.
Foundation Medicine Labs for Global Coverage
Cambridge, MA Shanghai, CHina
Morrisville, NC Hangzhou, CHina
Penzberg, germany
Commercially available in over 60 countries.
select a show
AACR 2020 ASCO 2020
May 28 - 31, 2020
Foundation Medicine at the ASCO 2020 Virtual Scientific Program
Advancing precision medicine in oncology

We’re excited to share our work in advancing precision medicine in oncology at this year’s American Society of Clinical Oncology (ASCO) Virtual Scientific Program. With a portfolio of tests including both tissue and blood-based comprehensive genomic profiling (CGP), we are able to identify known and novel genomic biomarkers to help inform treatment selection across all cancers.

This year we’re sharing data on the unique ability of comprehensive genomic profiling (CGP) to investigate nuanced biomarkers to advance precision treatment approaches, liquid biopsy as a proven way to access CGP testing with strong concordance to tissue-based CGP, and the newly druggable MET exon 14 skipping alterations in NSCLC.

ASCO 2020
Abstract Acceptance Summary
Oral Presentations
  • Abstract/Poster Number: 9511
  • Foundation Medicine Lead Author: Jessica Kim Lee
Poster Presentations
  • Abstract/Poster Number: 3517; 247
  • Foundation Medicine Lead Author: Jessica Kim Lee
  • Abstract/Poster Number: 1050; 135
  • Foundation Medicine Lead Author: Ethan Sokol
  • Abstract/Poster Number: 4579; 187
  • Foundation Medicine Lead Author: Jeffrey S. Ross, Ethan Sokol
  • Abstract/Poster Number: TPS2087; 79
  • Foundation Medicine Lead Author: Sarah Gaffey
  • Abstract/Poster Number: 5017; 86
  • Foundation Medicine Lead Author: Jeffrey S. Ross
  • Abstract/Poster Number: 3060; 124
  • Foundation Medicine Lead Author: Alexa Schrock
  • Abstract/Poster Number: 4620; 228
  • Foundation Medicine Lead Author: Ethan Sokol
  • Abstract/Poster Number: 11541; 429
  • Foundation Medicine Lead Author: Jeffrey S. Ross
  • Abstract/Poster Number: 5066; 135
  • Foundation Medicine Lead Author: Jeffrey S. Ross
  • Abstract/Poster Number: 1053; 138
  • Foundation Medicine Lead Author: Jeffrey S. Ross, Kimberly McGregor
  • Abstract/Poster Number: 5087; 156
  • Foundation Medicine Lead Author: Jeffrey S. Ross
  • Abstract/Poster Number: 11029; 286
  • Foundation Medicine Lead Author: Molly Hurley
  • Abstract/Poster Number: 11521; 409
  • Foundation Medicine Lead Author: Jonathan Keith Killian
  • Abstract/Poster Number: 3622; 352
  • Foundation Medicine Lead Author: Jonathan Keith Killian
  • Abstract/Poster Number: 6056; 227
  • Foundation Medicine Lead Author: Contributors; Matt Brosnan, Jessica Lee
  • Abstract/Poster Number: 3620; 350
  • Foundation Medicine Lead Author: Karthikeyan Murugesan
  • Abstract/Poster Number: 3558; 288
  • Foundation Medicine Lead Author: Ethan Sokol
  • Abstract/Poster Number: 5527; 108
  • Foundation Medicine Lead Author: Jeffrey S. Ross
  • Abstract/Poster Number: e23530
  • Foundation Medicine Lead Author: Alexa Schrock
Foundation Medicine
News Spotlight
Press Release
Foundation Medicine and Dana-Farber Present Data at ASCO20 Showing that Comprehensive Genomic Profiling Identified Co-Occurring Alterations that May Cause Treatment Resistance in Patients with METex14-altered NSCLC
FMI Press Release
Foundation Medicine, Inc. and Dana-Farber Cancer Institute presented new data highlighting the utility of comprehensive genomic profiling (CGP) to guide treatment decisions in patients with advanced non-small cell lung cancer (NSCLC) whose tumors also have an alteration that leads to MET exon 14 skipping (METex14).
Read More
Press Release
Foundation Medicine and Collaborators to Present New Data at ASCO 2020
FMI Press Release
Foundation Medicine, Inc. today announced that new data supporting the clinical use of its portfolio of tissue and liquid comprehensive genomic profiling (CGP) tests will be presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, which will be held from May 29 to May 31.
Read More
Blog Post
Liquid Biopsy: From an Improbable Idea, New Potential Emerges
Prasanth Reddy & Lucas Dennis
It’s always been an ambitious concept: By analyzing a patient’s blood, doctors might better understand their individual cancer, and thus better pinpoint what treatment options may be most effective. But yesterday’s ambition has become today’s reality—we’re living in an exciting time for this kind of test, known as liquid biopsy.
Read More
June 22 - 24, 2020
Foundation Medicine at the AACR Annual Meeting 2020
Advancing precision medicine in oncology

We’re excited to share our work in advancing precision medicine in oncology at this year’s American Society of Clinical Oncology (ASCO) Virtual Scientific Program. With a portfolio of tests including both tissue and blood-based comprehensive genomic profiling (CGP), we are able to identify known and novel genomic biomarkers to help inform treatment selection across all cancers.

This year we’re sharing data on the newly druggable MET exon 14 skipping alterations in NSCLC, liquid biopsy as a proven way to access CGP testing with strong concordance to tissue-based CGP, and the unique ability of CGP to investigate nuanced biomarkers to advance precision treatment approaches, particularly in rare cancer subtypes.

AACR 2020
Abstract Acceptance Summary
Poster Presentations
  • Abstract/Poster Number: 2337 / 21
  • Foundation Medicine Lead Author: Ben Kaplan
  • Abstract/Poster Number: LB-063 / 12
  • Foundation Medicine Lead Author: Ethan Sokol
  • Abstract/Poster Number: 3538 / 11
  • Foundation Medicine Lead Author: Dexter Jin
  • Abstract/Poster Number: 5455 / 3
  • Foundation Medicine Lead Author: Yanmei Huang
  • Abstract/Poster Number: 1017 / 12
  • Foundation Medicine Lead Author: Jeff Ross
  • Abstract/Poster Number: 5869 / 19
  • Foundation Medicine Lead Author: Ethan Sokol
  • Abstract/Poster Number: 6323 / 6
Foundation Medicine
News Spotlight
Blog Post
Liquid Biopsy: From an Improbable Idea, New Potential Emerges
Prasanth Reddy & Lucas Dennis
It’s always been an ambitious concept: By analyzing a patient’s blood, doctors might better understand their individual cancer, and thus better pinpoint what treatment options may be most effective. But yesterday’s ambition has become today’s reality—we’re living in an exciting time for this kind of test, known as liquid biopsy.
Read More
Blog Post
An end-to-end approach to precision medicine: MET exon 14 skipping mutations in non-small cell lung cancer (NSCLC)
Garrett Frampton
Earlier this month, FoundationOne CDx was approved to identify mutations that lead to MET exon 14 skipping in advanced non-small cell lung cancer (NSCLC) and match patients with a new targeted therapy, which was approved in parallel. This simultaneous approval presents a new treatment option for the 2-3% of lung cancer patients with cancers driven by METex14.
Read More
Blog Post
The Future of TMB as a Predictor of Immunotherapy Response Depends on Harmonization
David Fabrizio
The arrival of the American Association of Cancer Research (AACR) annual meeting this week was accompanied by mixed feelings for me. AACR has always been the first big opportunity of the year for the oncology community to come together, share the latest research and debate the high-profile topics of the moment. The reality of a virtual meeting was a stark reminder of how the coronavirus pandemic was impacting the cancer community as a whole.
Read More
Connect with us
Sources
  1. https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet#what-types-of-targeted-therapies-are-available Accessed April 2020
  2. ClinicalTrials.gov. Search for Active, not recruiting Studies, Oncology, United States on 8/28/2019. Retrieved from https://clinicaltrials.gov/ct2/results?cond=Oncology&cntry=US&Search=Apply&recrs=d&age_v=&gndr=&type=&rslt=
  3. IQVIA Institute for Human Data Science. (May 2019). Global Oncology Trends 2019; Therapeutics, Clinical Development and Health System Implications. Retrieved from https://www.iqvia.com/institute/reports/global-oncology-trends-2019
1. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019C.pdf
2. https://www.clinical-lung-cancer.com/article/S1525-7304(18)30204-3/fulltext#tblS1
3. https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet#what-types-of-targeted-therapies-are-available Accessed April 2020
EGFR
  1. https://www.sciencedirect.com/science/article/pii/S009377541830191X
  2. https://www.uptodate.com/contents/personalized-genotype-directed-therapy-for-advanced-non-small-cell-lung-cancer/print
KRAS
  1. https://www.frontiersin.org/articles/10.3389/fonc.2019.00953/full
  2. https://www.jto.org/article/S1556-0864(18)33532-9/fulltext
  3. https://www.mycancergenome.org/content/alteration/kras-amplification/
  4. https://esmoopen.bmj.com/content/4/Suppl_2/e000524
  5. https://neogenomics.com/diagnostic-services/test-spotlight/alk-ros1-fish-for-nsclc
BRAF
  1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301492/pdf/ol-09-02-0709.pdf
  2. https://www.uptodate.com/contents/personalized-genotype-directed-therapy-for-advanced-non-small-cell-lung-cancer/print My Cancer Genome
ALK
  1. https://www.uptodate.com/contents/personalized-genotype-directed-therapy-for-advanced-non-small-cell-lung-cancer/print
ERBBS
  1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205822/
  2. https://www.mycancergenome.org/content/alteration/erbb2-amplification/
  3. https://www.mycancergenome.org/content/alteration/erbb2-exon-20-insertion/
  4. https://www.mycancergenome.org/content/alteration/erbb2-d769y/
MET
  1. https://jhoonline.biomedcentral.com/articles/10.1186/s13045-019-0759-9
  2. https://www.uptodate.com/contents/personalized-genotype-directed-therapy-for-advanced-non-small-cell-lung-cancer/print
  3. https://www.mycancergenome.org/content/alteration/met-fusion/
ROS1
  1. https://www.uptodate.com/contents/personalized-genotype-directed-therapy-for-advanced-non-small-cell-lung-cancer/print
  2. https://www.mycancergenome.org/content/alteration/ros1-g2032r/
NTRK
  1. https://www.uptodate.com/contents/personalized-genotype-directed-therapy-for-advanced-non-small-cell-lung-cancer/print
RET
  1. https://www.uptodate.com/contents/personalized-genotype-directed-therapy-for-advanced-non-small-cell-lung-cancer/print
  2. https://cancerdiscovery.aacrjournals.org/content/candisc/early/2018/06/12/2159-8290.CD-18-0338.full.pdf
STK11
  1. https://www.lungcancerjournal.info/article/S0169-5002(19)30005-4/fulltext
  2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410347/#SD1
  1. Rozenblum AB, et al. J Thorac Oncol. 2017;12(2):258-68.
  2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.2.2020
  3. Neil Vasan et al. Science 2019; 366:714-723, Foundation Medicine Pub summary sheet https://science.sciencemag.org/content/366/6466/714.full
  4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.3.2019
  5. Hussain M, Mateo J, Fizazi K, et al. PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. Presented at ESMO Congress 2019; September 27-October 1, 2019; Barcelona, Spain. Abstract LBA12_PR.
  6. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.4.2019
  7. Rankin A, Klempner SJ, Erlich R, et al. Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. The Oncologist. 2016.
  8. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon Cancer V.1.2020
  9. As calculated in FoundationCore as of January 2018.
  10. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myleoproliferative Neoplasms V.3.2019
  11. Boussemart et al. Hybrid-capture based genomic profiling identifies BRAF V600 and non-V600 alterations in melanoma samples negative by prior testing. ESMO 2017.
  12. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Cutaneous Melanoma V.1.2020
  13. Keytruda (pembrolizumab) [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; 2014.
  14. Hellman MD, et al. N Eng J Med. 2018;378(22):2093-104.
  15. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Esophageal and Esophagogastric Junction Cancers V.4.2019
  16. Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC. NCT03178552. Annals of Oncology, Volume 30, Supplement 5, October 2019
  17. Dearden et al. Ann Oncol. 2013 Sep; 24(9): 2371–2376.
  18. Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors, J Chung et al, JCO Precision Oncology, May 2019.
  19. Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC. NCT03178552. Annals of Oncology, Volume 30, Supplement 5, October 2019
  20. Dearden et al. Ann Oncol. 2013 Sep; 24(9): 2371–2376.
  21. Chung JH, Dewal N, Sokol E, et al. Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors. JCO Precis Oncol. 2019;3:10.1200/PO.18.00283.
  1. Frampton GM, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotech 2013;11:1023-1033.
  2. Drilon A, et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in “driver-negative” lung adenocarcinomas. Clin Cancer Res 2015;21:3631-3639.
  3. Rozenblum AB, et al. Clinical impact of hybrid capture-based next-generation sequencing on changes in treatment decisions in lung cancer. J Thorac Oncol 2017;12(2):258-68.
  4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Cutaneous Melanoma V.1.2020
  5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Esophageal and Esophagogastric Junction Cancers V.4.2019
  6. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.2.2020
  1. Chawla et. al. JCO Precision Oncology 2018 :2, 1-11
  2. Drilon A, et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in “driver-negative” lung adenocarcinomas. Clin Cancer Res 2015;21:3631-3639
  3. Gray PN, et al. Not all next Generation sequencing diagnostics are created equal: understanding the nuances of solid tumor assay design for somatic mutation detection. Cancers 2015;7:1313-32.
  4. Jardim DL, et al. Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval
  5. Suh JH, et al. Comprehensive genomic profiling facilitates implementation of the National Comprehensive Cancer Network Guidelines for lung cancer biomarker testing and identifies patients who may benefit from enrollment in mechanism-driven clinical trials. The Oncologist 2016;21:684-91.
  6. Suh JH, et al. Comprehensive genomic profiling facilitates implementation of the National Comprehensive Cancer Network Guidelines for lung cancer biomarker testing and identifies patients who may benefit from enrollment in mechanism-driven clinical trials. The Oncologist 2016;21:684-91.
  1. Qualifying Medicare and Medicare Advantage members have coverage of FoundationOne®CDx in accordance with the Centers for Medicare and Medicaid Services (CMS) national coverage determination (NCD) criteria
  1. Graham RP, et al. Hum Pathol. 2014;45:1630‒1638.
  2. Johann de Bono, M.B., et al (2020). Olaparib for Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine. doi: 10.1056/nejmoa1911440
  3. https://onlinelibrary.wiley.com/doi/full/10.3322/caac.21560
  4. Vuong HG, Ho ATN, Altibi AMA, Nakazawa T, Katoh R, Kondo T. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer – A systematic review and meta-analysis. Lung Cancer. 2018;123:76-82.
  1. Neil Vasan et al. Science 2019; 366:714-723, FMI Pub summary sheet https://science.sciencemag.org/content/366/6466/714.full
  2. LBA81_PR ‘Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC: initial results from ALK+ cohort’ will be presented by Shirish Gadgeel during the proffered paper session on Monday, 30 September 2019, 08:30-10:00 CEST in Madrid Auditorium (Hall 2). Annals of Oncology, Volume 30, Supplement 5, October 2019
  3. Dearden et al. Ann Oncol. 2013 Sep; 24(9): 2371–2376.
  1. [Leukemia & Lymphoma Society] Burd, et al.: Precision Medicine Treatment in elderly AML: Results of Beat AML Master Trial (oral; abstract 175; Dec. 7, 12 pm)
  2. Seligson, et al. “Comprehensive genomic analysis of EWSR1-NFATc2 fusion sarcomas identify distinctive.” Abstract presented at CTOS 2019.
† As defined by the number of cancer pa margin-top:5%; tients tested by Foundation Medicine in a clinical setting with comprehensive genomic profiling and the amount of evidence published by Foundation Medicine in a research setting about comprehensive genomic profiling
  1. Unique patient specimens tested by Foundation Medicine and in Foundation Medicine’s database of cancer genomic profiles as of January 2020
  2. Medicare and Medicare Advantage members have coverage of FoundationOne®CDx in accordance with the Centers for Medicare and Medicaid Services (CMS) national coverage determination (NCD) criteria. TRICARE members have coverage for FoundationOne®CDx pursuant to TRICARE’s medical policy and patient benefit plans.
  3. All commercial payer coverage is pursuant to the applicable payer’s medical policy and specific patient benefit plans. Foundation Medicine's FoundationOne®Heme and FoundationOne®Liquid tests have limited commercial payer coverage.
  1. Roche Media Release, 2018. Available at: https://www.roche.com/media/releases/med-cor-2018-06-19.htm (Accessed March 2019).